Salute e Benessere

Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of…

The two sensors, implanted in patients who received LVADs at New York-Presbyterian/Columbia, join the 5 microsensors already implanted in Israel under similar conditions. "Implantation of the microsensor was easy and took about 5 minutes, requiring a minimal modification to the LVAD implantation procedure," Dr. Takeda said. The two sensors, implanted in patients who received LVADs at New York-Presbyterian/ Columbia, join the 5 microsensors already implanted inIsraelunder similar…
PR Newswire
09/06/2025

Amicomed by Newel Health obtains EU MDR certification as a digital medical…

In addition to its direct-to-consumer application, Amicomed can be deployed as a digital companion to antihypertensive therapies. It supports medication adherence and generates longitudinal behavioral insights. The solution has also been validated in population health programs for cardiovascular risk monitoring and chronic care optimization, as well as in digital insurance models focused on prevention and risk management. These use cases create pathways for adoption across pharmaceutical…
PR Newswire
09/06/2025

Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on…

Company management including Hitto Kaufmann, Chief R&D Officer, and Elisabeth Sonesson, VP, Global Franchise Lead Autoimmunity, will highlight current activities and anticipated milestones for the Company in the autoimmune space. Company management including Hitto Kaufmann, Chief R&D Officer, andElisabeth Sonesson, VP, Global Franchise Lead Autoimmunity, will highlight current activities and anticipated milestones for the Company in the autoimmune space. A live Q&A will follow the...
PR Newswire
09/06/2025

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARSParis, June 9, 2025, 8am CETAB Science SA(Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to 48 months. This shelf-life extension applies to the 50mg tablet strength of MASIVET® currently available in the EU.MASIVET® is currently approved for the treatment...
Nasdaq GlobeNewswire
09/06/2025

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING

UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETINGNantes, June 9th, 2025, 8 a.m.-OSE Immunotherapeutics SA( ISIN: FR0012127173; Mnemo: OSE)informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled for 25 June 2025 (the “ General Meeting ”).In preparation of the General Meeting, OSE Immunotherapeutics has formally submitted to the President of the Nantes Commercial Court a request to extend the date of the General Meeting...
Nasdaq GlobeNewswire
09/06/2025

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare…

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025.Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Immunizations begin in early fall and these advance shipments provide confidence for healthcare providers to support their efforts...
Nasdaq GlobeNewswire
09/06/2025

Zealand Pharma increases its share capital as a result of the exercise of…

Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025–Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a...
Nasdaq GlobeNewswire
06/06/2025

Fagron increases share capital through exercise subscription rights

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 85,000 new shares have been issued on 6 June 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 504,303,905.59. The total number of shares with voting rights after the issue amounts...
Nasdaq GlobeNewswire
06/06/2025

Spineway : Minutes of the General Meeting of June 4, 2025

Press release Ecully, June 6, 2025 – 6.00 p.m. SPINEWAYMinutes of the General Meeting of June 4, 2025 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice onWednesday, June 4, 2025 at 2:00 p.mat the company’s registered office, 7 allée Moulin Berger in Ecully (69).The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the...
Nasdaq GlobeNewswire
06/06/2025

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 6 June 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS (" GEM "), the Company's share capital has increased on 6 June 2025 from EUR…
Nasdaq GlobeNewswire
06/06/2025

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 6 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entity listed below, notifying the number of voting rights attached to the shares mentioned next to its name in the table below…
Nasdaq GlobeNewswire
06/06/2025

Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR |…

Browse in-depth TOC on "Healthcare Simulation Market" Browse in-depth TOC on "Healthcare Simulation Market" 150 - Tables 50 - Figures 359 - Pages By Based on product & service,the healthcare simulation market, by product & service, is segmented into healthcare simulation anatomical models, healthcare simulation software, web-based simulation, and simulation training services. In 2024, the anatomical models accounted for the largest market share, driven by the...
PR Newswire
06/06/2025

Functional Gummies Market to Hit USD 2.4 Billion by 2030, Driven by Vegan &…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-7B5529/Global_Functional_Gummies_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-7B5529/Global_Functional_Gummies_Market Major Factors Driving the Growth of Functional Gummies Market: The functional gummies market is experiencing robust growth as it aligns with evolving consumer preferences for health, convenience, and experience. This market sits at the intersection...
PR Newswire
06/06/2025

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy…

"The one-year Phase 3 results are very compelling, confirming Aspaveli's sustained benefits across key markers of disease," said Fadi Fakhouri, M.D., PhD, presenting author, co-lead principal investigator for the VALIANT study, and professor of nephrology at CHUV Lausanne, Switzerland. "Given the high risk of kidney failure, treatment efficacy is incredibly important to C3G and primary IC-MPGN patients, many of whom are in the prime of their lives. These data further underscore…
PR Newswire
06/06/2025

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT…
Nasdaq GlobeNewswire
06/06/2025

Biodefense Market worth $1.81 billion by 2030 - Exclusive Report by…

Browse in-depth TOC on "Biodefense Market" 196 – Tables56 – Figures217 – Pages Browse in-depth TOC on "Biodefense Market" 196 – Tables 56 – Figures 217 – Pages Biodefense Market Report Scope: Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Based on application, the hospitals & medical institutes segment is expected to account for the largest share of…
PR Newswire
06/06/2025

The Galien Foundation Announces 2025 Prix Galien UK Award Winners Recognising…

"This year's submissions were of exceptional caliber, making the task of selecting winners both challenging and inspiring. The awardees have demonstrated groundbreaking progress in their fields, and their work holds great promise for patients worldwide," said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool, NHS Chair of Pharmacogenetics, and Chair of the Prix Galien UK Committee. "This year's submissions were of exceptional…
PR Newswire
06/06/2025

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND…

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025Halle (Saale) / Munich, Germany, June 6, 2025– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon),a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62 ndERA...
Nasdaq GlobeNewswire
06/06/2025

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI®…

Under the terms of the MSA, OBI grants TegMine rights to utilize OBI’s GlycOBI® ADC enabling technologies, powered by EndoSymeOBI® and HYPrOBI® , to identify ADC therapeutics candidates for potential clinical development. If an ADC product candidate(s) is ensued, OBI and TegMine would enter into a formal licensing agreement.“This strategic collaboration leverages the synergistic strengths of both organizations,” noted Heidi Wang, Ph.D., OBI Pharma’s Chief Executive Officer...
Nasdaq GlobeNewswire
06/06/2025

HTL Biotechnology inaugurates a new production line dedicated to sterile…

The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations…
PR Newswire
06/06/2025

Nicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June…

Press ReleaseNicox: Notice of the Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025 and appointment of anad hocrepresentative June 6, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company's headquarters located at...
Nasdaq GlobeNewswire
06/06/2025

Idorsia publishes invitations to bondholder meetings

Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and CB 2028 Allschwil, Switzerland – June 6, 2025Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period for the amended terms approved at the CB 2025 bondholder meeting of February 25, 2025 – during which no appeal was filed – it has published invitations to...
Nasdaq GlobeNewswire
06/06/2025

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025- Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to...
Nasdaq GlobeNewswire
06/06/2025

ZEISS CLARUS 700 Receives NMPA Approval in China

"ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina…
PR Newswire
06/06/2025
Altri  Comunicati